ERBB2 and breast cancer: In a cohort of 12 HER2-positive breast cancer patients treated with trastuzumab, interrogation of DNA methylation using the Infinium HumanMethylation450 BeadChip allowed identifying genes that were differentially methylated between trastuzumab-resistant and trastuzumab-sensitive HER2-positive breast cancer patients.